CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lung cancer.
  
  LEARNING OBJECTIVES

  • Counsel patients with metastatic non-small cell lung cancer (NSCLC) with EGFR mutations regarding available therapies, explaining the relevance of mutation type and other clinical factors.
  • Communicate the efficacy and safety of approved ALK inhibitors to appropriate patients with NSCLC.
  • Assess available research with approved RET inhibitors, and use this information to appropriately educate patients with newly diagnosed and progressive NSCLC.
  • Convey the clinical relevance of a positive KRAS G12C mutation test result to patients with NSCLC, and appreciate available research findings with approved agents demonstrating efficacy in these individuals.
  • Recollect other oncogenic pathways such as MET and HER2 mediating the pathogenesis of tumors in unique patient subsets, and recall published data with commercially available agents exploiting these targets.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies in the treatment of NSCLC, and discern how these approaches can be optimally employed.
  • Discern the side effects and toxicities associated with targeted agents, immune checkpoint inhibitors and other available novel approaches for NSCLC, and implement strategies to manage and mitigate them.
  • Recall new and emerging data with novel agents and strategies currently under investigation for metastatic NSCLC, and consider the role these may soon play in disease management.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY —The following faculty reported relevant financial relationships with ineligible entities:
  
  Stephen V Liu, MD
  Associate Professor of Medicine
  Georgetown University Hospital
  Washington, DC
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Merus BV, Mirati Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Contracted Research: Alkermes, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Merus BV, Nuvalent, RAPT Therapeutics, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: Candel Therapeutics.
  
  Tara Plues, APRN, MSN
  Hematology and Medical Oncology
  Cleveland Clinic
  Cleveland, Ohio
  
  No relevant conflicts of interest to disclose.
  
  Jillian Thompson, MSN, ANP-BC, AOCNP
  Nurse Practitioner
  MedStar Georgetown University Hospital
  Lombardi Comprehensive Cancer Center
  Washington, DC
  
  Advisory Committee: Janssen Biotech Inc; Nonrelevant Financial Relationship: Targeted Oncology (virtual tumor board).
  
  Anne S Tsao, MD, MBA
  Vice President, Academic Affairs
  Chief Academic Office
  Professor, Thoracic/Head and Neck Medical Oncology
  Director, Mesothelioma Program
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc, Summit Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Epizyme Inc, Genentech, a member of the Roche Group, Lilly, Merck, Novartis, Polaris Pharmaceuticals, Seagen Inc, Takeda Pharmaceuticals USA Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Mirati Therapeutics Inc, and Novocure Inc.
  
  Release date: May 2023
  Expiration date: May 2024
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.